Crispr Therapeutics shares tumble after significant earnings miss
Jessica Denecour, a director at PG&E Corp (NYSE:PCG), recently purchased 1,347 shares of common stock at a price of $15.79 per share. This acquisition, dated February 21, 2025, amounts to a total value of approximately $21,269. Following this transaction, Denecour’s direct ownership in the company stands at 59,803.08 shares. The transaction was part of routine activities and reflects Denecour’s ongoing investment in PG&E Corp.
In other recent news, PG&E Corporation reported its fourth-quarter earnings for 2024, showing a slight miss on earnings per share (EPS), which came in at $0.31 against the forecasted $0.32. Revenue also fell short, reaching $6.63 billion compared to the expected $7.19 billion. Despite the quarterly miss, PG&E achieved an 11% year-over-year increase in core EPS to $1.36 for the full year. Looking forward, the company has updated its 2025 EPS guidance range to $1.48-$1.52, reflecting confidence in its operational strategies. BMO Capital Markets recently raised its price target for PG&E from $21.00 to $23.00, maintaining an Outperform rating. Analyst James Thalacker noted PG&E’s strong operational performance, aligning with consensus EPS estimates. Additionally, PG&E completed a $2.75 billion equity offering in December, which is part of its broader capital investment plan aimed at supporting a 10% rate base growth through 2028.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.